News

Madhav V. Dhodapkar, MBBS, discusses some of the immunotherapies under investigation and those that are being highlighted at the 20th International Myeloma Society Annual Meeting for patients with multiple myeloma.

Priority review to the biologics license application for odronextamab has been granted by the FDA for adult patients with follicular lymphoma and diffuse large B-cell lymphoma.

Findings from a systematic review on the efficacy of bispecific antibodies were presented during the 20th International Myeloma Society Annual Meeting.

Daniel P. Petrylak, MD, discusses background and findings from the phase 3 KEYNOTE-921 study of pembrolizumab plus docetaxel vs placebo plus docetaxel in patients with metastatic castration-resistant prostate cancer who had received prior next-generation hormonal agent therapy.

Results of the phase 3 MIRASOL study evaluating mirvetuximab soravtansine for platinum-resistant ovarian cancer will be announced at an upcoming meeting.

John M. Burke, MD, discusses how Bruton tyrosine kinase inhibitors have demonstrated unexpected promise in treating follicular lymphoma, challenging previous assumptions in the field of oncology.

Topline results from MARIPOSA reveal a survival advantage with amivantamab plus lazertinib vs osimertinib in patients with EGFR-mutant non–small cell lung cancer. Additional follow-up is planned.

Joshua Richter, MD, evaluates the efficacy and safety data of linvoseltamab for the treatment of patients with multiple myeloma.

IDE161 now has 2 fast track designations from the FDA for patients with breast cancer and ovarian cancer. The agent continues to be evaluated in a first-in-human, phase 1 study for patients with advanced solid tumors.

Researchers presented updated results from longer-term follow-up studies of GC012F for newly-diagnosed multiple myeloma treatment at the International Myeloma Society Annual Meeting.

Cyrus M. Khan, MD, discusses the phase 1/2 trial of glofitamab for use as a treatment option for patients with relapsed/refractory large B-cell lymphoma.

The Isa-KRd combination in the GMMG-CONCEPT trial yielded high MRD negativity rates among patients with newly diagnosed, high-risk multiple myeloma, irrespective of transplant status.

Robert Dreicer, MD, MS, MACP, FASCO, acknowledges that there have been substantial developments in therapies and strategies for treating prostate cancer, leading to heightened expectations of breakthroughs in the field.

Richard S. Finn, MD, and R. Kate (Katie) Kelley, MD, emerged in a discussion about the factors that inform treatment decisions for patients with hepatocellular carcinoma during the International Liver Cancer Association Annual Conference 2023.

Treatment with CAN-2409 produced promising survival data and continues to show a favorable safety and tolerability profile for the treatment of non-resectable, stage III/IV non–small cell lung cancer.

The ADVANCED-2 trial plans to build onto the early antitumor and safety data seen with TARA-002 that were presented this year for patients with non-muscle invasive bladder cancer.

Bosutinib has a new indication in leukemia as a well as a newly-approved formulation.

In an interview with Targeted Oncology, Richard S. Finn, MD, discussed his ILCA Annual Conference 2023 presentation on optimal frontline treatment in hepatocellular carcinoma and how this standard of care could evolve in the future.

ABM-1310 is an investigational small molecule BRAF inhibitor that is being development for the treatment of various BRAF V600E-mutant solid tumors.

Findings from the largest group of patients with BRCA1/2-altered metastatic castration resistant prostate cancer are now available.

In an interview, Chung-Han Lee, MD, PhD, discussed the challenges, studies, and outcomes previously observed when studying adjuvant treatments for patients with renal cell carcinoma.

The investigational antibody-drug conjugate, MYTX-011, is one step further in development for the treatment of non–small cel lung cancer with cMET overexpression.

Experienced healthcare leader brings 25 years of expertise in real-world data, analytics, and strategic planning.

Findings from a phase 1 support the fast track designation given by the FDA to IDE161, a potent, selective, small-molecule inhibitor of PARG, for patients with BRCA1/2 mutant ovarian cancer.

The FDA has issued a complete response letter for the biologics license application seeking the approval of the on-body injector presentation of pegfilgrastim-cbqv, but has not requested additional findings or clinical trials.

Results from the phase 3 NETTER-2 study will be presented at an upcoming medical conference and shared with drug regulators.

Following positive phase 1 results, HPN328 treatment in now under evaluation in a phase 1/2 trial.

John Lister, MD, discusses the current role of stem cell transplant in the treatment of T-cell lymphoma, and some of the latest advances in the space.

C. Ola Landgren, MD, PhD, discussed the ASCENT trial and his predictions for future developments in the myeloma space.

A phase 2 study, PUMA-ALI-4201, will further investigate alisertib for the treatment of small cell lung cancer.